Neuroblastoma is an embryonal tumor that typically arises in cells of the developing adrenal medulla. IGF-II mRNA is expressed at high levels in the adrenal cortex before birth but it is not detectable until after birth in the adrenal medulla. Neuroblastoma cell lines corresponding to early adrenal medullary precursors did not express IGF-II, although all three cell lines we tested were growth stimulated by IGF-II. Cell lines corresponding to more mature adrenal medullary cells expressed IGF-II, and one, SK-N-AS, grows by an IGF-II autocrine mechanism (J. Clin. Invest. 84:829-839) El-Badry, Romanus, Helman, Cooper, Rechler, and Israel. 1989. An examination of human neuroblastoma tumor tissues for IGF-II gene expression using in situ hybridization histochemistry revealed that IGF-II is expressed by tumor cells in only 5 of 21 neuroblastomas, but is detectable in cells of nonmalignant tissues including adrenal cortical cells, stromal fibroblasts, and eosinophils in all 21 tumors. These findings indicate that IGF-II may function as an autocrine growth factor for some neuroblastomas and as a paracrine growth factor for others. They suggest that the growth regulatory pathways utilized by neuroblastoma mimic those used in the precursor cell type from which individual tumors arise. (J. Clin. Invest. 1991. 87:648-657.)
Introduction
Insulin-like growth factor II (IGF-II)' and IGF-I are chemically similar peptides that share sequence homology with insulin (1) . Although distinct cell surface receptors have been identified for IGF-I and IGF-II, both peptides are thought to stimulate growth by binding to the type I IGF receptor (2) (3) (4) (5) . IGF-I mediates the growth promoting effects of growth hormone during postnatal growth (6, 7) . In contrast, IGF-II is thought to be involved in fetal growth and development: IGF-II mRNA is detected at higher levels in rat and human fetal tissues than in the corresponding adult tissues (8) (9) (10) ; IGF-II has growth promoting effects on fetal cells in vitro (1 1, 12) ; and fetal tissues display type I IGF receptors on their cell surface (13) (14) (15) . Expression of high levels of IGF-II mRNA in a number ofhuman embryonal and adult tumors relative to the levels observed in the corresponding tissues of adults (10, (16) (17) (18) (19) has raised the possibility that IGF-II might contribute to the neoplastic proliferation of tumor cells that express high levels of IGF-II.
Neuroblastoma is a highly malignant tumor of infants and young children (median age at presentation 2 y) that accounts for up to 50% of all malignancies among infants (20) . Neuro- blastomas arise in cells of neural crest origin destined to become chromaffin tissue or neurons of the peripheral nervous system (21) . We previously found that IGF-II can mediate the autocrine growth of SK-N-AS neuroblastoma cells (22) . Although our studies using Northern blot analysis indicated that IGF-II mRNA was expressed in only a minority of neuroblas- tomas, all ofthese tumors expressed the gene encoding the type I IGF receptor (22) . We therefore undertook studies to examine further the role of IGF-II in the proliferation of these tumors.
Methods
Cell lines and cell culture. Human neuroblastoma cells (Table I; see   reference 23 for origins of cell lines) were cultured in RPMI 1640 medium containing 10% FBS (Biofluids, Rockville, MD), penicillin (50 U/ml), streptomycin (50 Mg/ml) and L-glutamine (2 mM), and were incubated at 370C in a humidified incubator containing 5% CO2. SK-N-AS cells were cultured in serum-free N2E medium and incubated in 6% CO2 (22) .
Cell multiplication assays. In preparation for growth assays, SK-N-BE(2), SK-N-DZ, and LA-N-I cells were removed from serum by a step-wise transfer from medium containing 10% FBS to medium containing 5% FBS and then 1% FBS (one passage at each concentration, 7 d each). This medium was twice replaced with serum-free N2E medium containing insulin (1 Mg/ml) (Sigma Chemical Co., St. Louis, MO). The first replacement was at 72, and the second at 24 h before the initiation of growth assays. SK-N-AS cells were continuously cultured in N2E medium without serum or growth factors (22 (24) was examined by Northern blot analysis using a 32P-labeled plasmid DNA probe containing a cDNA insert encoding rat IGF-II (pr-IGF-II-l, 780-bp insert in pUC12) (8, 22) that was labeled to a specific activity of 2-4 X 108 cpm/.g DNA. Neuroblastoma and normal human adrenal gland tissues (6-uM sections) were processed and examined by in situ hybridization (25) using 5 x 105 cpm of a 31-bp synthetic DNA sequence specific for IGF-II (corresponding to nucleotides 535 to 565 [22, 26] (4, 5, 22, 27, 28) , a receptor which is detectable in RNA from all neuroblastoma cell lines (8 of 8) and tumors (8 of 8) we have examined, as well as in RNA from adrenal medulla, the tissue from which most neuroblastomas are thought to arise (22; and data not shown). We further pursued the role of IGF-II in the growth of neuroblastoma tumors for the following reasons: (a) neuroblastoma is an embryonal tumor and IGF-II is expressed at high levels in the human fetus whereas IGF-I is not (29) ; (b) IGF-II mRNA had been detected in 3 of 12 neuroblastomas previously examined (10, 22, 30, 31) ; and (c) the growth ofone human neuroblastoma cell line, SK-N-AS, is mediated by endogenously produced IGF-II (22) . In contrast, IGF-I is not expressed in poly A+ selected mRNA from neuroblastoma cell lines, and is not detectable in culture medium conditioned by human neuroblastoma cells (22; and data not shown). Also, IGF-II expression has been documented in a large number of different embryonal tumors (e.g., [16] [17] [18] [19] Other work from our laboratory has suggested that neuroblastoma cell lines correspond to cells that occur at different stages in the maturation of adrenal medullary chromaffin cells (23) . We therefore correlated IGF-II gene expression in neuroblastoma cell lines (Fig. 2 , Table I ) with their degree of chromaffin cell maturation (23) . As illustrated in Table I, gene expression in neuroblastoma cell lines was detected only in cell lines that we previously determined to express markers of mature adrenal medullary cells (23) .
IGF-II mRNA is expressed by malignant cells ofsome neuroblastomas and by nonmalignant cells ofall these tumors. To determine which cells of neuroblastoma tumor tissue express IGF-II, we examined IGF-II gene expression in 21 neuroblastoma specimens using in situ hybridization histochemistry (26; see Methods). We detected IGF-II gene expression in tumor cells of 5 of the 21 neuroblastomas evaluated ( Fig. 3 ; and data not shown). IGF-II was expressed at -10 times the background level in one tumor (Fig. 3, A-D (Figs. 4 and 5 ). These tissues included adrenal cortical cells (Fig. 4, A and B) . IGF-II expression in such cells was observed in 4 of the 7 neuroblastomas that contained adrenal cortical tissue. IGF-II expression was also detected in neuroblastoma tumor stroma (Fig. 4 , C-F) and capsular tissue (Fig. 4 , E and F) composed primarily of fibroblasts (Fig. 4, C-F) . IGF-II expression in stroma was observed in 9 ofthe 20 specimens that contained stromal tissue. Expression of IGF-II in capsular tis- In all of the 21 neuroblastomas examined, we detected hybridization of our IGF-II probe to eosinophils (Fig. 5) . These cells were observed within sheets of tumor cells (data not shown) and in nonmalignant tissues associated with neuroblastomas including hemorrhagic (Fig. 5, Cand D) , stromal (Fig. 5 , E-G), and vascular tissues (data not shown). We also detected such cells in a lymph node (Fig. 5, A and B ) and pancreatic tissue (data not shown) associated with metastatic neuroblastomas. We observed marked differences in both the number of eosinophils and the grain counts over eosinophils in the different tumors analyzed ( Fig. 5 ; and data not shown).
IGF-II is expressed at high levels in human fetal adrenal cortical cells. Because of the potential importance of arrested differentiation in the pathogenesis of neuroblastoma (21) we examined normal fetal, childhood, and adult adrenal gland tissues for the expression of IGF-II. Fig. 6 (A and B) illustrates IGF-II expression in adrenal gland tissues from a 7-8 wk gestation embryo. The hybridization signal was highest in fetal adrenal cortical cells but was also detectable in the neocortex. At 9-10 wk of gestation IGF-II expression was still detectable at low levels in the neocortex but had declined dramatically in fetal adrenal cortex relative to the levels observed at 7-8 wk of gestation (Fig. 6, C and D) . By 20 wk gestation (Fig. 6, E and F .VI .
-i --4S . (22), we were unable in repeated studies to detect expression by in situ hybridization (Fig. 6, I and J).
Discussion
The proliferation of a human neuroblastoma cell line, SK-N-AS, is mediated by endogenously produced IGF-II (22) . However, we observed that many neuroblastoma cell lines grow poorly when plated at low density into medium without growth factors.
In this study we demonstrate that exogenously added IGF-II stimulates the growth of several human neuroblastoma cell lines in a dose-dependent manner (Fig. 1) . Together with our finding that IGF-II is expressed in cells of nonmalignant tissues associated with neuroblastoma tumor cells (Figs. 4 and 5), these data indicate that locally produced IGF-II may stimulate the proliferation of neuroblastoma.
IGF-II-mediated growth of neuroblastoma requires appropriate receptors through which this factor can stimulate cellular proliferation. IGF-II binds with high affinity to at least two receptors: the type I IGF receptor, an IGF sensitive tyrosinespecific protein kinase, and the type II/mannose-6-phosphate receptor (2, 3, 32) . Only the type I receptor has been shown to mediate the mitogenic activities of IGF-II (4, 5) . Using 1251 IGF-I, Shigematsu et al. (14) detected type I IGF receptors in cells of both the fetal and adult human adrenal medulla and cortex. We previously reported type I IGF receptor gene expression in both adrenal medullary and cortical tissue and in 8 of8 human neuroblastoma tumors (22) . Cell surface type I IGF receptors have also been demonstrated on SH-SY5Y human neuroblastoma cells (33, 34) and in neuroblastomas from rats (35) and mice (36) . Moreover, the type I IGF receptors on SK-N-AS neuroblastoma cells bind IGF-II and mediate IGF-II-induced [3H]thymidine uptake in these cells (22) .
Although the proliferation ofsome neuroblastomas may be mediated by an IGF-II autocrine mechanism (22; and Figs. 2 and 3), our demonstration of IGF-II gene expression in cells of tumor stroma, capsule, adrenal cortical tissues, and tumor infiltrating eosinophils (Figs. 4 and 5) suggests that IGF-II pro-duced by nonmalignant cells either within or adjacent to neuroblastoma tumors may function in a paracrine manner to stimulate their proliferation. Particularly noteworthy is the observation of IGF-II gene expression in adrenal cortical tissue adjacent to tumor (Fig. 4) , but not in such tissue obtained from patients without adrenal tumors. It will be important to determine whether the synthesis ofthis growth-stimulatory ligand in nonmalignant tissues associated with neuroblastoma tumor cells is mediated by tumor-derived factors. Other studies demonstrating IGF-II expression in established fibroblast cell lines and in benign and malignant human breast tissue (37) have raised the possibility that locally produced IGFs may also mediate the growth of other human tumors as well (38) .
IGF-II gene expression has been detected in both parenchymal and stromal tissue of many different embryonic organs (10, 26, 29; and this study), suggesting that IGF-II may function normally in the human fetus to promote growth. Studies in our laboratory have suggested that neuroblastoma tumor cell lines correspond to adrenal chromaffin cells that are recognizable at different times during development (23, 39) . IGF-II mRNA and protein is detected in adult adrenal medulla (17, 22) and neuroblastoma cell lines that express markers associated with mature adrenal medullary tissue (Fig. 2 , Table I ) (23) . This finding is compatible with the origin of such tumors in adrenal medullary cells that expressed IGF-II at the time of their malignant transformation. The proliferation of these tumors may not require exogenous sources ofIGF-II (e.g., SK-N-AS cells [22] ). In contrast, neuroblastomas containing tumor cells that do not express IGF-II may be dependent upon exogenous IGF-II, potentially from adjacent stroma or other normal tissues (Figs. 4 and 5) . Such tumors may arise from more primitive adrenal medullary cells (Table I) , which do not express IGF-II but are surrounded during development by tissues that express very high levels ofthe gene (Fig. 6 ). These observations suggest that the growth mechanisms mediating the proliferation of neuroblastoma tumor cells may be the same mechanisms mediating the growth of normal medullary cells during adrenal organogenesis.
A majority of the patients diagnosed with neuroblastoma present with metastases to adjacent lymph nodes, bones, liver, or skin (20) . Significantly, all ofthese tissues express high levels of IGF-II mRNA or protein at the times during development when neuroblastomas are detected in such tissues (10, 26, 29, 30, 40, 41 , and this study). In contrast, metastatic neuroblastoma is rarely detected in brain and lung, common sites of metastases for other pediatric tumors. These tissues do not express high levels of IGF-II in the human fetus or adult (10, 42, 43) . Observations that IGF-II can function as a chemoattractant (44, 45) raise the possibility that neuroblastomas metastasize to specific tissues due to the influence of IGF-II produced by these tissues. Alternatively, neuroblastomas may metastasize to various sites throughout the body and proliferate only in tissues that contain high concentrations of IGF-II. Neuroblastomas in which tumor cells express high levels of IGF-II mRNA, a minority of the tumors examined to date, may survive in other tissues such as lung that express little or no IGF-II.
Neuroblastomas of low clinical stage in children under 1 yr of age and stage IVS disease often regress without cytotoxic therapy (46, 47) . Such tumors may be detected in the adrenal, liver, and skin (47) . IGF-II expression in these tissues has been shown to decline from high levels observed early during gestation to low levels noted by birth or shortly after birth (10, 
